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Drug targeting systems are nanometre-sized carrier materials designed for improving the biodistribution of systemically applied
(chemo)therapeutics. Various different tumour-targeted nanomedicines have been evaluated over the years, and clear evidence is
currently available for substantial improvement of the therapeutic index of anticancer agents. Here, we briefly summarise the most
important targeting systems and strategies, and discuss recent advances and future directions in the development of tumour-targeted
nanomedicines.
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Over the past few decades, our knowledge on the aetiology of
cancer has increased exponentially (Hanahan and Weinberg,
2000). This improved understanding of the processes that are at
the heart of malignant transformation and tumorigenesis has
resulted in the development of several new classes of antitumour
therapeutics. In addition to classical chemotherapeutic agents (like
doxorubicin, cisplatin and paclitaxel), these so-called ‘molecularly
targeted therapeutics’ (like growth factor receptor inhibitors,
proteasome inhibitors, histone deacetylase inhibitors and anti-
angiogenic agents) have enriched the therapeutic armoury with
their ability to more selectively interfere with certain ‘hallmarks of
cancer’. An important, but often neglected property that such
second-generation agents share with classical chemotherapeutic
drugs, however, is their unfavourable biodistribution upon
intravenous administration: the agents are generally rapidly
cleared from the circulation, and only a very small fraction
reaches the tumour site. Moreover, in certain situations, reaching
the tumour is not enough: the drug may be cleared from the
tumour too rapidly and may not be available long enough to
display a strong therapeutic effect. Also, the physicochemical
properties of the drug may make it difficult for the drug to
enter the target cells. Tumour-targeted nanomedicines are
drug delivery systems being developed in oncology to improve
drug performance by overcoming such limitations (Table 1). Their
most striking feature is their ability to target a drug to the tumour
site, thereby enhancing tumoral drug levels (site-specific delivery;
aiming for enhanced antitumour activity), and/or to direct a drug
away from those body sites that are particularly sensitive to the
toxic effects of the drug (site-avoidance delivery; aiming for
reduced damage to normal tissues). In this review, we briefly
address the most important nanomedicine systems and strategies,
summarise the clinical status and highlight future directions.
PASSIVE DRUG TARGETING
Tumour-targeted nanomedicines currently in clinical use are
shown in Figure 1. Most of these systems utilise the so-called
‘passive targeting’ concept, with the exception of antibodies and
their fragments, which use a receptor recognition motif for
improving the delivery of the drug (through ‘active targeting’).
By designing the systems such that a long circulation time is
achieved, significant accumulation in tumours is obtained,
especially in those tumour areas with active angiogenesis. Passive
targeting refers to the substantial extravasation of the nanomedi-
cine-associated drug into the interstitial fluid at the tumour site,
exploiting the locally increased vascular permeability (Figure 2B).
In addition, solid tumours tend to lack functional lymphatics, and
extravasated (nano)materials are retained within the tumour site
for prolonged periods of time. The exploitation of this so-called
‘enhanced permeability and retention’ (EPR) effect is currently
the most important strategy for improving the delivery of
low-molecular-weight (chemo)therapeutic agents to tumours
(Maeda et al, 2000; Torchilin, 2005; Duncan, 2006).
Liposomes
Liposomes are frontrunners among the nanomedicine systems
developed so far (Bangham et al, 1965; Gregoriadis, 1976).
Liposomes are self-assembling colloid structures composed of
lipid bilayers surrounding (an) aqueous compartment(s), and can
encapsulate a wide variety of (chemo)therapeutic agents. Myocet
and Caelyx (Doxil in the United States) were among the first of
such lipid self-assemblies to be approved by the regulatory
authorities (Table 2). Both products contain doxorubicin, but
differ particularly in the presence of a ‘stealth’ coating: the former
refers to doxorubicin entrapped in uncoated liposomes, and the
latter to liposomes surface-modified (or ‘sterically stabilized’) with
poly(ethylene glycol) (PEG) to reduce rapid recognition by the
reticuloendothelial system, and thereby to prolong circulation time
(Drummond et al, 1999; Torchilin, 2005).
The pharmacokinetic benefits of liposomal drug encapsulation
can be illustrated as follows: for free doxorubicin, an elimination
half-life time of 0.2h and an AUC (area under the curve) of
4mghml
 1 were found in patients, as compared with 2.5h and
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Caelyx, respectively (Hofheinz et al, 2005). Both in animal models
and in patients, such (liposome-mediated) improvements in AUC
have been shown to result in significant improvements in (EPR-
mediated) drug targeting to tumours (Drummond et al, 1999;
Torchilin, 2005). However, thus far, the primary justification for
approving liposomal anthracyclines has been their ability to
attenuate drug-related toxicity (e.g., cardiomyopathy, bone
marrow depression, alopecia and nausea), rather than to enhance
antitumour efficacy. A phase III head-to-head comparison of free
doxorubicin vs Myocet in patients with metastatic breast cancer,
for instance, demonstrated in this regard that at comparable
response rates (RR: 26% for both) and progression-free survival
times (PFS: 4 months for both), the incidence of cardiac events (29
vs 13%) and of congestive heart failure (8 vs 2%) were significantly
lower for Myocet (Harris et al, 2002). Also for Caelyx, significantly
reduced cardiomyopathy was observed, whereas its response rates,
its PFS times and its overall survival times were always at least
comparable with those of the free drug (Drummond et al, 1999;
Hofheinz et al, 2005; Torchilin, 2005). In certain specific cases, for
example in patients suffering from AIDS-related Kaposi’s sarco-
mas, which are characterized by a dense and highly permeable
vasculature, Caelyx not only reduced the toxicity of the interven-
tion but also substantially improved its efficacy: as compared with
the formerly standard combination regimen ABV (i.e., adriamycin
(doxorubicin), bleomycin and vincristine), which produced a
partial response in 31 out of 125 patients (RR¼25%), Caelyx
achieved 1 complete response and 60 partial responses (RR¼46%;
Northfelt et al, 1998). Caelyx has consequently been approved for
Kaposi’s sarcoma, and is currently also marketed for metastatic
breast cancer, advanced ovarian cancer and multiple myeloma.
Besides Myocet and Caelyx, several other liposomal nanomedi-
cines have been evaluated over the years, including, for example,
non-PEGylated liposomal daunorubicin (DaunoXome) and
vincristine (Onco-TCS), PEGylated liposomal cisplatin (SPI-77)
and lurtotecan (OSI-211), and lipoplexes, such as Allovectin and
LErafAON, in which cationic lipids are used to complex, carry,
protect and deliver genetic material, such as plasmid DNA and
antisense oligonucleotides (Table 2). Thermodox, a temperature-
sensitive version of liposomal doxorubicin (that can be triggered
to release its contents; see Figure 2E), has also recently entered
clinical trials. At the preclinical level, numerous additional
liposomal nanomedicines have been tested, aiming not only to
establish novel carrier–drug combinations (Schiffelers et al, 2006),
but also to improve the efficacy of already existing formulations,
for example, by optimising the composition of the lipid bilayer
(Drummond et al, 1999), or by the nature or density of the
polymeric stealth coatings (Romberg et al, 2007).
Polymers
Ten years after the first report on liposomes (Bangham et al, 1965),
and coinciding with the appreciation of their clinical potential
(Gregoriadis, 1976), natural and synthetic polymers started to
attract attention as drug delivery systems. Conceptualised by
Ringsdorf (1975), it was envisioned that polymeric macro-
molecules can be conjugated to pharmacologically active agents
by means of linkers that are stable in blood, but labile in the acidic
and/or enzymatic conditions typical of, for example, the tumour
microenvironment or certain intracellular compartments. These
so-called ‘polymer therapeutics’ have been shown to passively
accumulate in tumours by means of the EPR effect, and to be able
to beneficially affect the therapeutic index of attached low-
molecular-weight agents (Duncan, 2006).
In 1994, a conjugate called PK1 was the first tumour-targeted
polymeric prodrug to enter clinical trials. In PK1, doxorubicin is
conjugated to the prototypic polymeric drug carrier PHPMA
(poly(N-(2-(hydroxypropyl)methacrylamide)) through an enzyma-
tically cleavable tetrapeptide spacer (GFLG). Like Myocet and
Caelyx, PK1 primarily improved the therapeutic index of
doxorubicin by attenuating its (cardio)toxicity (Duncan, 2006).
This is exemplified by the remarkably high maximum tolerated
dose observed for PK1 in clinical trials, being 45 times higher
than that determined for free doxorubicin (320 vs 60mgm
 2;
Vasey et al, 1999). Following this proof of principle, PK1
Table 1 Characteristics of an ideal tumour-targeted nanomedicine
(1) Increase drug localisation in the tumour through:
(a) Passive targeting
(b) Active targeting
(2) Decrease drug localisation in sensitive, non-target tissues
(3) Ensure minimal drug leakage during transit to target
(4) Protect the drug from degradation and from premature clearance
(5) Retain the drug at the target site for the desired period of time
(6) Facilitate cellular uptake and intracellular trafficking
(7) Biocompatible and biodegradable
Note that not all characteristics apply to all types of nanomedicines.
Liposome
Polymer–drug
conjugate
Protein–drug
conjugate Polymeric micelle Antibody–drug
conjugate
PEGylated
liposome Lipoplex/Polyplex Polymer–protein
conjugate
Figure 1 Examples of clinically used tumour-targeted nanomedicines. Representative examples of clinically used tumour-targeted nanomedicines.
Liposomal bilayers are depicted in grey, polymers and polymer-coatings in green, biodegradable linkers (for releasing drugs and polymer coatings) in blue,
targeting ligands in yellow, antibody fragments in purple, radionuclides in orange and the conjugated or entrapped (chemo)therapeutic agents in red.
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polymer therapeutics entered clinical trials (Table 2).
In 2005, Abraxane (i.e., albumin-bound paclitaxel) was the first
passively tumour-targeted polymeric nanomedicine to gain Food
and Drug Administration (FDA) approval. Evidence for an
advantage of Abraxane over the standard, Cremophor-formulated
version of paclitaxel has been provided by a large phase III trial in
which 4400 women with metastatic breast cancer were rando-
mized to receive either Abraxane (260mgm
 2 given as a 30-min
infusion, without premedication) or the free drug (i.e., Taxol;
175mgm
 2 given as a 3-h infusion, with standard steroid and
antihistamine premedication). As compared with Taxol, Abraxane
significantly improved both the response rate (33 vs 19%) and the
PFS time (23 vs 17 weeks) of systemic taxane treatment (Gradishar
et al, 2005), and at the same time, it also attenuated its toxicity: the
incidence of grade 4 neutropenias was significantly lower for
Abraxane (9 vs 22%), despite the 50% higher dose, and no
hypersensitivity reactions were observed, despite the absence of
premedication (Gradishar et al, 2005).
Besides Abraxane and PK1, a number of additional polymeric
nanomedicines have been evaluated clinically (Table 2). Oncaspar,
for instance, in which the polymer PEG is conjugated to the protein
L-asparaginase (to decrease allergic reactions and frequency of
administration), has been used for treating patients with acute
lymphoblastic leukemia for 410 years; Zinostatin, that is, PSMA-
bound neocarcinostatin, has been approved in Japan for the
treatment of liver cancer; and Xyotax, that is, PLGA-conjugated
paclitaxel, is in phase III evaluation for ovarian and non-small-cell
lung cancer. In addition to such conventional polymer–drug,
polymer–protein and protein–drug conjugates, several novel
types of polymeric nanomedicines have also recently entered
clinical trials, including cationic polyplexes for DNA and siRNA
delivery (De Smedt et al, 2001; Schiffelers et al, 2004), dendrimers
(Bai et al, 2006), and polymeric micelles (Nishiyama and Kataoka,
2006).
ACTIVE DRUG TARGETING
In active drug targeting, targeting ligands are attached to drugs
and drug delivery systems to act as homing devices for binding to
receptor structures expressed at the target site (Allen, 2002; Park
et al, 2004). Antibody–drug conjugates targeted to, for example,
CD20, CD25 and CD33, which are (over)expressed in non-
Hodgkin’s lymphoma, T-cell lymphoma and acute myeloid
leukaemia, respectively, have been successfully used for delivering
radionuclides (Zevalin), immunotoxins (Ontak) and antitumour
antiobiotics (Mylotarg) more selectively to tumour cells (Table 2).
Antibodies, antibody fragments and peptides have also been
used as targeting moieties for drug delivery systems. Clinical
evidence in support of this strategy, however, is scarce, and has to
date only been provided for galactosamine-targeted PHPMA-
doxorubicin (PK2) (Seymour et al, 2002) and GAH-targeted
doxorubicin-containing immunoliposomes (MCC-465) (Matsumura
et al, 2004): for the former, responses were observed in 3 out of 31
patients with liver cancer (with one partial remission lasting for
A
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BC
Endothelial cell targeting Triggered drug release Local drug delivery
Tumour Tumour
Normal
tissue
Tumour
O2
Nutrients
Normal
tissue
Tumour
Normal
tissue
Tumour
Normal
tissue
Normal
tissue
Tumour
Normal
tissue
Free drug Passive drug targeting Cancer cell targeting
Figure 2 Overview of the clinically most relevant drug targeting strategies. (A) Upon the intravenous injection of a low-molecular-weight
(chemo)therapeutic agent, which is often rapidly cleared from blood, only low levels of the drug accumulate in tumours and in tumour cells, whereas their
localisation to certain healthy organs and tissues can be relatively high. (B) Upon the implementation of a passively targeted drug delivery system, by virtue of
the enhanced permeability and retention (EPR) effect, the accumulation of the active agent in tumours and in tumour cells can be increased substantially. (C)
Active drug targeting to internalization-prone cell surface receptors (over)expressed by cancer cells generally intends to improve the cellular uptake of the
nanomedicine systems, and can be particularly useful for the intracellular delivery of macromolecular drugs, such as DNA, siRNA and proteins. (D) Active
drug targeting to receptors (over)expressed by angiogenic endothelial cells aims to reduce blood supply to tumours, thereby depriving tumour cells from
oxygen and nutrients. (E) Stimuli-sensitive nanomedicines, such as Thermodox, can be activated (i.e., induced to release their contents) by externally applied
physical triggers, such as hyperthermia, ultrasound, magnetic fields and light. (F) In cases in which tumours are easily accessible, for example during surgery,
sustained-release delivery devices can be implanted or injected directly into (the irresectable parts of the) tumours.
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in 10 out of 18 patients with gastric cancer (but no obvious
reductions in tumour size).
Preclinically, a much larger number of studies have dealt with
actively targeted nanomedicines, and several general principles
have emerged. In most cases in which the nanosized carrier
materials were targeted to receptors (over)expressed by cancer
cells, for instance, the observed improvements in antitumour
efficacy were found to be due to an enhanced cellular internalisa-
tion of the agents, rather than to an increased tumour accumula-
tion (Figure 2C; Park et al, 2004; Kirpotin et al, 2006). The fact that
improving cellular internalisation can – at least under certain
circumstances – improve the efficacy of systemic anticancer
therapy has resulted in the design of delivery systems targeted to
endocytosis-prone surface receptors, such as the transferrin
receptor, the folate receptor and EGFR (Allen, 2002; Torchilin,
2005; Duncan, 2006). In addition, it has stimulated research into
the use of cell-penetrating peptides and protein-transduction
domains, such as oligo-arginine and TAT, to enable the
internalisation of agents that would otherwise not be taken up
effectively by cancer cells (Gupta et al, 2005).
Destruction of the endothelium in solid tumours can result in
the death of tumour cells induced by the lack of oxygen and
nutrients. This observation, together with the high accessibility of
luminal surface receptors, has led to the design of nanomedicines
actively targeted to tumour endothelial cells (Figure 2D). Ligands
used to target drugs and/or drug delivery systems to tumour blood
vessels include the antibody fragment L19 (Neri and Bicknell,
2005), which uses the EDB domain of the oncofetal protein
fibronectin to home to angiogenic vasculature, and several cyclic
and linear derivatives of the oligopeptides RGD and NGR, which
bind to angiogenic endothelium through the integrins a2bb3, avb3
and a5b1, and through aminopeptidase-N, respectively. Recent
data obtained in our group with RGD-targeted liposomes
containing vascular targeting agents showed widespread central
necrosis in established experimental tumours (Fens et al,
submitted). Opposite to the short-lasting antitumour effects
obtained with the free agent, endothelial cell-targeted liposomal
delivery halted tumour progression for significantly prolonged
periods of time. Further preclinical and clinical studies on the
efficacy of tumour vasculature-targeted nanomedicines are eagerly
awaited. If such nanomedicines ultimately prove in the clinic to be
efficacious with manageable side effects, combination therapies
together with radiation, chemotherapeutic agents and/or anti-
angiogenic drugs are anticipated to attack the thin film of viable
tumour cells in the periphery of the tumour, which usually
survives when vascular targeting agents are applied as anticancer
therapeutics.
FUTURE DIRECTIONS
In this review, we have primarily restricted ourselves to tumour-
targeted nanomedicines designed for the improved delivery of
already established, low-molecular-weight chemotherapeutics.
Many of the new drugs arising from advances in biotechnology,
however, are macromolecules, such as proteins and nucleic acids.
The clinical development of these challenging and often fragile
molecules will likely also profit substantially from the attributes of
targeted nanomedicines, providing these complex molecules, for
example, with protection against degradation and elimination, and
with improved access to target cells and tissues.
In the document ‘Forward Look on Nanomedicine’, the European
Science Foundation included in their definition of the discipline of
nanomedicine not only the use of nanometer-sized materials for the
treatment but also for the diagnosis of diseases. Regarding the latter
aspect, the development of high-resolution imaging techniques (such
as, MRI and PET) for the rapid, noninvasive monitoring of the in vivo
fate and performance of targeted nanomedicines is currently receiving
intense attention, and will certainly facilitate the implementation of
imaging-guided drug delivery to promote the optimal use of (tumour-)
targeted nanomedicines.
Table 2 Examples of clinically used tumour-targeted nanomedicines
Compound Name Indication Status
Liposomal doxorubicin Myocet, Caelyx (Doxil) Breast, ovarian, KS Approved
Liposomal daunorubicin Daunoxome Kaposi sarcoma Approved
Liposomal vincristine Onco-TCS Non-hodgkin lymphoma Approved
Liposomal cisplatin SPI-77 Lung Phase II
Liposomal lurtotecan OSI-221 Ovarian Phase II
Cationic liposomal c-Raf AON LErafAON Various Phase I/II
Cationic liposomal E1A pDNA PLD-E1A Breast, ovarian Phase I/II
Thermosensitive liposomal doxorubicin ThermoDox Breast, liver Phase I
Albumin-paclitaxel Abraxane Breast Approved
Albumin-methotrexate MTX-HSA Kidney Phase II
Dextran-doxorubicin DOX-OXD Various Phase I
PEG-L-asparaginase Oncaspar Leukaemia Approved
PEG-IFNa2a/ IFNa2b PegAsys/PegIntron Melanoma, leukaemia Phase I/II
PHPMA-doxorubicin PK1 Breast, lung, colon Phase II
Galactosamine-targeted PK1 PK2 Liver Phase I/II
PGA-paclitaxel Xyotax Lung, ovarian Phase III
Paclitaxel-containing polymeric micelles Genexol-PM Breast, lung Phase II
Cisplatin-containing polymeric micelles Nanoplatin Various Phase I
Doxorubicin-containing polymeric micelles NK911 Various Phase I
SN38-containing polymeric micelles LE-SN38 Colon, colorectal Phase I
90Yttrium-Ibritumomab tiuxetan (a-CD20) Zevalin Non-hodgkin lymphoma Approved
DTA-IL2 fusion protein (a-CD25) Ontak T-cell lymphoma Approved
Ozogamycin-gemtuzumab (a-CD33) Mylotarg Leukaemia Approved
Doxorubicin-cBR96 (a-CD174) SGN-15 Lung, prostate, breast Phase II
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years to come are:
(1) the design of systems that are able to respond to externally
applied stimuli, such as, hyperthermia, ultrasound, light and
magnetic fields, and that can be triggered to release their
contents (like Thermodox; Figure 2E);
(2) the targeting of agents other than conventional chemo-
therapeutic drugs to tumours, such as, anti-inflammatory
agents (e.g., corticosteroids) to inhibit tumour-associated
inflammation (Schiffelers et al, 2006), and siRNA to reduce
the expression of proteins essential for tumour progression
(Schiffelers et al, 2004);
(3) the development of systems that are able to simultaneously
deliver multiple therapeutic agents to tumours, such as
temporally targeted ‘nanocells’, which first release the
anti-angiogenic agent combrestatin and subsequently the
chemotherapeutic agent doxorubicin (Sengupta et al, 2005);
(4) the translation of the experience gained in oncology into
applications for improving the treatment of other diseases,
such as rheumatoid arthritis, Crohn’s disease, autoimmune
diseases and infections, which are all highly amenable to
(EPR-mediated) drug targeting (Schiffelers et al, 2006); and
(5) the establishment of treatment regimens in which tumour-
targeted nanomedicines are combined with other clinically
relevant treatment modalities, such as with surgery, with
radiotherapy and with (standard) chemotherapy.
For obvious reasons, the latter of the above strategies has thus
far received the most clinical attention. During surgery, for
instance, sustained-release delivery devices, such as Gliadel (i.e.,
carmustine-containing polymeric wafers), can be implanted into
those parts of glioblastoma lesions that cannot be removed
surgically (see Figure 2F). In addition to this, also systems
originally intended for systemic administration, such as polymers
and liposomes, have been shown to hold potential for such local
interventions (Lammers et al, 2006). Regarding radiotherapy,
preclinical and early clinical evidence suggest that tumour-targeted
nanomedicines and radiotherapy interact synergistically, with
radiotherapy improving the tumour accumulation of the delivery
systems, and with the delivery systems improving the interaction
between radiotherapy and chemotherapy (Li et al, 2000; Dipetrillo
et al, 2006; Lammers et al, 2008). And regarding chemotherapy,
both Myocet and Caelyx have been successfully included in several
different combination chemotherapy trials (Hofheinz et al, 2005),
and also for Abraxane initial results obtained in combination
regimens are promising. Combinations of molecularly targeted
therapeutics with tumour-targeted therapeutics have also already
been evaluated, showing, for example, that the combination of
Avastin (Bevacizumab) with Abraxane produced an overall
response rate of almost 50% in heavily pretreated breast cancer
patients (Link et al, 2007).
Since the approval, in 1995, of the first tumour-targeted
anticancer nanomedicine (Caelyx/Doxil, i.e., stealth liposomal
doxorubicin), targeted nanomedicines have become an established
addition to the anticancer drug arsenal, with several formulations
presently on the market. A major limitation impeding the entry of
targeted nanomedicines onto the market is that new concepts and
innovative research ideas within academia are not being developed
and exploited in collaboration with the pharmaceutical industry.
An integrated ‘bench-to-clinic’ approach, realised within a
structural collaboration between industry and academia, would
strongly stimulate the progression of tumour-targeted nanomedi-
cines towards clinical application.
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